The expanding field of biologics in the management of chronic urticaria

Shyam Joshi, David A. Khan

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab. This review will focus on the data surrounding the management of CU with omalizumab, off-label use of other biologics for CU, and biologics currently under investigation for use in CU. We will also discuss management considerations and areas of interest for future research.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
StateAccepted/In press - 2017


  • Biologics
  • Chronic urticaria
  • Mechanism
  • Monoclonal antibody
  • Omalizumab
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'The expanding field of biologics in the management of chronic urticaria'. Together they form a unique fingerprint.

Cite this